首页> 外文期刊>Current Medicinal Chemistry >Always Around, Never the Same: Pathways of Amyloid Beta Induced Neurodegeneration Throughout the Pathogenic Cascade of Alzheimer's Disease
【24h】

Always Around, Never the Same: Pathways of Amyloid Beta Induced Neurodegeneration Throughout the Pathogenic Cascade of Alzheimer's Disease

机译:永远存在,永远不一样:整个Alzheimer病的致病级联过程中,淀粉样蛋白β诱导神经变性的途径

获取原文
获取原文并翻译 | 示例
           

摘要

There is an increasing amount of evidence showing the importance of intermediate aggregation species of amyloid β (Aβ) in the pathogenic cascade of Alzheimer's disease (AD). Different Aβ assembly forms may mediate diverse toxic effects at different stages of the disease. Mouse models for AD suggest that intraneuronal accumulation of Aβ oligomers might be involved in AD pathogenesis at a very early stage of the disease. The detrimental effect of oligomeric Aβ on synaptic efficacy is suggested to be an early event in the pathogenic cascade. Also early neuronal responses as activation of the unfolded protein response are processes likely to be associated with the increased occurrence of oligomeric or low fibrillar Aβ in AD pathology. In later stages of AD pathology, the fibrillarity of Aβ increases, concomitantly with a neuroinflammatory response, followed by tau related neurofibrillary changes in end stage pathology. We will review recent findings in in vitro cell models, in vivo mouse models, and post mortem AD brain tissue in view of the effects of different Aβ peptide species on neurodegeneration during AD pathogenesis. Insight into the role of different Aβ species during AD pathogenesis is essential for the development of disease modifying drugs and therapeutical strategies.
机译:越来越多的证据表明,淀粉样蛋白β(Aβ)的中间聚集物种在阿尔茨海默病(AD)的致病级联中的重要性。不同的Aβ组装形式可能在疾病的不同阶段介导不同的毒性作用。 AD的小鼠模型表明,在疾病的早期,Aβ寡聚体的神经内神经蓄积可能与AD发病有关。提示寡聚Aβ对突触功效的有害作用是致病级联反应的早期事件。同样,早期神经元反应作为未折叠蛋白反应的激活也是可能与AD病理学中寡聚或低原纤维Aβ发生率增加相关的过程。在AD病理的后期,Aβ的纤维性增加,伴随着神经炎性反应,随后在末期病理中tau相关的神经原纤维改变。鉴于不同的Aβ肽种类对AD发病过程中神经退行性变的影响,我们将回顾体外细胞模型,体内小鼠模型和验尸AD脑组织中的最新发现。深入了解不同Aβ物种在AD发病机理中的作用对于开发疾病改良药物和治疗策略至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号